Top

Published in:

Open Access 01-12-2024 | Ovarian Cancer | Research

Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data

Published in: BMC Cancer | Issue 1/2024

Abstract

Background

Ovarian cancer (OC) is a complex disease with significant tumor heterogeneity with the worst prognosis and highest mortality among all gynecological cancers. Glycosylation is a specific post-translational modification that plays an important role in tumor progression, immune escape and metastatic spread. The aim of this work was to identify the major glycosylation-related genes (GRGs) in OC and construct an effective GRGs signature to predict prognosis and immunotherapy.

Methods

AUCell algorithm was used to identify glycosylation-related genes (GRGs) based on the scRNA-seq and bulk RNA-seq data. An effective GRGs signature was conducted using COX and LASSO regression algorithm. The texting dataset and clinical sample data were used to assessed the accuracy of GRGs signature. We evaluated the differences in immune cell infiltration, enrichment of immune checkpoints, immunotherapy response, and gene mutation status among different risk groups. Finally, RT-qPCR, Wound-healing assay, Transwell assay were performed to verify the effect of the CYBRD1 on OC.

Results

A total of 1187 GRGs were obtained and a GRGs signature including 16 genes was established. The OC patients were divided into high- and low- risk group based on the median riskscore and the patients in high-risk group have poor outcome. We also found that the patients in low-risk group have higher immune cell infiltration, enrichment of immune checkpoints and immunotherapy response. The results of laboratory test showed that CYBRD1 can promote the invasion, and migration of OC and is closely related to the poor prognosis of OC patients.

Conclusions

Our study established a GRGs signature consisting of 16 genes based on the scRNA-seq and bulk RNA-seq data, which provides a new perspective on the prognosis prediction and treatment strategy for OC.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed

Nasioudis D, Sisti G, Kanninen TT, Holcomb K, Di Tommaso M, Fambrini M, Witkin SS. Epidemiology and outcomes of squamous ovarian carcinoma; a population-based study. Gynecol Oncol. 2016;141(1):128–33.CrossRefPubMed

Hoang G, Udupa S, Le A. Application of metabolomics technologies toward cancer prognosis and therapy. Int Rev Cell Mol Biol. 2019;347:191–223.CrossRefPubMed

Ali MY, Liaqat F, Khazi MI, Sethupathy S, Zhu D. Utilization of glycosyltransferases as a seamless tool for synthesis and modification of the oligosaccharides-A review. Int J Biol Macromol. 2023;249:125916.CrossRefPubMed

Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188464.CrossRefPubMed

Fernández-Ponce C, Geribaldi-Doldán N, Sánchez-Gomar I, Quiroz RN, Ibarra LA, Escorcia LG, Fernández-Cisnal R, Martinez GA, García-Cózar F, Quiroz EN. The role of glycosyltransferases in Colorectal Cancer. Int J Mol Sci. 2021;22(11).

Esmail S, Manolson MF. Advances in understanding N-glycosylation structure, function, and regulation in health and disease. Eur J Cell Biol. 2021;100(7–8):151186.CrossRefPubMed

Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(9):540–55.CrossRefPubMed

Meezan E, Wu HC, Black PH, Robbins PW. Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by sephadex chromatography. Biochemistry. 1969;8(6):2518–24.CrossRefPubMed

10.

Silsirivanit A. Glycosylation markers in cancer. Adv Clin Chem. 2019;89:189–213.CrossRefPubMed

11.

Moremen KW, Ramiah A, Stuart M, Steel J, Meng L, Forouhar F, Moniz HA, Gahlay G, Gao Z, Chapla D, et al. Expression system for structural and functional studies of human glycosylation enzymes. Nat Chem Biol. 2018;14(2):156–62.CrossRefPubMed

12.

Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, et al. Commonly occurring cell subsets in high-Grade Serous Ovarian tumors identified by single-cell Mass Cytometry. Cell Rep. 2018;22(7):1875–88.CrossRefPubMedPubMedCentral

13.

Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, Cen Y, Fei W, Zhang B, Shen Y, et al. Single-cell RNA sequencing reveals the tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clin Cancer Res. 2022;28(16):3590–602.CrossRefPubMedPubMedCentral

14.

Zhang P, Pei S, Gong Z, Feng Y, Zhang X, Yang F, Wang W. By integrating single-cell RNA-seq and bulk RNA-seq in sphingolipid metabolism, CACYBP was identified as a potential therapeutic target in lung adenocarcinoma. Front Immunol. 2023;14:1115272.CrossRefPubMedPubMedCentral

15.

Pei S, Zhang P, Chen H, Zhao S, Dai Y, Yang L, Kang Y, Zheng M, Xia Y, Xie H. Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer. Front Endocrinol (Lausanne). 2023;14:1135297.CrossRefPubMed

16.

Li Y, Lin Y, Aye L, Dong L, Zhang C, Chen F, Liu Y, Fan J, Gao Q, Lu H, et al. An integrative pan-cancer analysis of the molecular and biological features of glycosyltransferases. Clin Transl Med. 2022;12(7):e872.CrossRefPubMedPubMedCentral

17.

Okano M, Oshi M, Butash AL, Katsuta E, Tachibana K, Saito K, Okayama H, Peng X, Yan L, Kono K et al. Triple-negative breast Cancer with high levels of annexin A1 expression is Associated with mast cell infiltration, inflammation, and Angiogenesis. Int J Mol Sci 2019, 20(17).

18.

Zhang Y, Chen Y, Wen W. Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer. Front Immunol. 2023;14:1152806.CrossRefPubMedPubMedCentral

19.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–8.CrossRefPubMedPubMedCentral

20.

Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS ONE. 2007;2(11):e1195.CrossRefPubMedPubMedCentralADS

21.

Yang C, Huang X, Li Y, Chen J, Lv Y, Dai S. Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology. Brief Bioinform 2021, 22(3).

22.

Liu J, Geng R, Ni S, Cai L, Yang S, Shao F, Bai J. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. Mol Ther Nucleic Acids. 2022;27:1036–55.CrossRefPubMedPubMedCentral

23.

Bi F, Chen Y, Yang Q. Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int. 2020;20:373.CrossRefPubMedPubMedCentral

24.

Liu YS, Guo XY, Hirata T, Rong Y, Motooka D, Kitajima T, Murakami Y, Gao XD, Nakamura S, Kinoshita T, et al. N-Glycan-dependent protein folding and endoplasmic reticulum retention regulate GPI-anchor processing. J Cell Biol. 2018;217(2):585–99.CrossRefPubMedPubMedCentral

25.

Stowell SR, Ju T, Cummings RD. Protein glycosylation in cancer. Annu Rev Pathol. 2015;10:473–510.CrossRefPubMedPubMedCentral

26.

Mereiter S, Balmaa M, Campos D, Gomes J, Reis CA. Glycosylation in the era of Cancer-targeted therapy: where are we heading? Cancer Cell. 2019;36(1):6–16.CrossRefPubMed

27.

Xu J, Zhou J, Hu J, Ren Q, Wang X, Shu Y. Development and validation of a machine learning model for survival risk stratification after esophageal cancer surgery. Front Oncol. 2022;12:1068198.CrossRefPubMedPubMedCentral

28.

Ahmadieh-Yazdi A, Mahdavinezhad A, Tapak L, Nouri F, Taherkhani A, Afshar S. Using machine learning approach for screening metastatic biomarkers in colorectal cancer and predictive modeling with experimental validation. Sci Rep. 2023;13(1):19426.CrossRefPubMedPubMedCentralADS

29.

Lynch CM, Abdollahi B, Fuqua JD, de Carlo AR, Bartholomai JA, Balgemann RN, van Berkel VH, Frieboes HB. Prediction of lung cancer patient survival via supervised machine learning classification techniques. Int J Med Inform. 2017;108:1–8.CrossRefPubMedPubMedCentral

30.

Zhou CM, Xue Q, Wang Y, Tong J, Ji M, Yang JJ. Machine learning to predict the cancer-specific mortality of patients with primary non-metastatic invasive breast cancer. Surg Today. 2021;51(5):756–63.CrossRefPubMed

31.

Ji GW, Fan Y, Sun DW, Wu MY, Wang K, Li XC, Wang XH. Machine learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma after Surgical Resection. J Hepatocell Carcinoma. 2021;8:913–23.CrossRefPubMedPubMedCentral

32.

Christopherson KM, Das P, Berlind C, Lindsay WD, Ahern C, Smith BD, Subbiah IM, Koay EJ, Koong AC, Holliday EB, et al. A machine learning Model Approach to Risk-Stratify patients with gastrointestinal Cancer for hospitalization and mortality outcomes. Int J Radiat Oncol Biol Phys. 2021;111(1):135–42.CrossRefPubMed

33.

Li Z, Sillanpää MJ. Overview of LASSO-related penalized regression methods for quantitative trait mapping and genomic selection. Theor Appl Genet. 2012;125(3):419–35.CrossRefPubMed

34.

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500–1.CrossRefPubMedPubMedCentral

35.

Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125(9):3413–21.CrossRefPubMedPubMedCentral

36.

Grizzi G, MarioGkountakos. AnastasiosCarbognin, LuisaTortora, GiampaoloBria, EmilioPilotto, Sara: putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. Expert Rev Mol Diagn 2017, 17(7a12).

37.

Allgäuer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring J, et al. Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res. 2018;7(6):703–15.CrossRefPubMedPubMedCentral

38.

Zhang J, Song C, Tian Y, Yang X. Single-cell RNA sequencing in Lung Cancer: revealing phenotype shaping of stromal cells in the Microenvironment. Front Immunol. 2021;12:802080.CrossRefPubMed

39.

Altorki NK, Markowitz GJ, Gao D, Port JL, Saxena A, Stiles B, McGraw T, Mittal V. The lung microenvironment: an important regulator of tumour growth and metastasis. Nat Rev Cancer. 2019;19(1):9–31.CrossRefPubMedPubMedCentral

Title: Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data
Publication date: 01-12-2024
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11908-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Retraction Note: Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145

Construction of a prognostic model for hepatocellular carcinoma patients receiving transarterial chemoembolization treatment based on the Tumor Burden Score

High expression of TBRG4 in relation to unfavorable outcome and cell ferroptosis in hepatocellular carcinoma

Germline mutations in BRCA1 and BRCA2 among Brazilian women with ovarian cancer treated in the Public Health System

Mechanism of intestinal microbiota disturbance promoting the occurrence and development of esophageal squamous cell carcinoma——based on microbiomics and metabolomics

Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i

Keynote webinar | Spotlight on antibody–drug conjugates in cancer